Babu et al. also found that only five K17-positive cells were sufficient threshold for a positive test (AUC = 0.90), where SN ranged from 86% or 97%, the first for a biopsy-confirmed BC, the second in a discovery and validation cohort, while and SP of 100% for high-grade and 84% for biopsy-confirmed tumors (Babu et al. 2021). Here, KRT17 is linked to breast cancer.